Objective:To investigate the clinical characteristics and independent predictors of progression-free survival (PFS)in patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma in the real world.Methods:This was a retrospective observational study.The clinical data of 74 EGFR mutation-positive lung adenocarcinoma patients who visited the Geriatric Oncology Department of the Fisrt Affiliated Hospital of Nanjing Medical University from January 2020 to March 2025 were retrospectively collected.Retrospective analysis was performed on baseline clinical characteristics(gender, age, smoking history, stage, etc.), EGFR mutation types, and treatment follow-up data(PFS, treatment regimens). Descriptive statistics were used to summarize the baseline clinical characteristics of the patients.The distribution differences in clinical characteristics between the elderly group and the non-elderly group were compared.Kaplan-Meier survival curves were plotted with Log-rank test, and the Cox proportional hazards model was used to screen for independent prognostic factors.Results:The incidence of comorbidities in the elderly group(48.78%, 20/41)was significantly higher than that in the non-elderly group(24.24%, 8/33), with a statistically significant difference( χ2=4.681, P=0.031). No statistically significant differences were observed between groups in other variables[gender, stage, presence of multiple metastases, smoking history, Eastern cooperative oncology group (ECOG)score, treatment regimens, mutation types](all P>0.05). The median PFS (mPFS)in the elderly group was significantly shorter than that in the non-elderly group(18.20 months vs.26.78 months, Log-rank χ2=3.930, P=0.047). No significant differences in mPFS were found among gender, stage, presence of multiple metastases, smoking history, comorbidity status, ECOG score, treatment regimens, EGFR mutation types or types of tyrosine kinase inhibitor(TKI)(all P>0.05). Multivariate Cox regression further confirmed that advanced age(≥65 years)is an independent predictor of shortened PFS( HR=2.67, 95% CI: 1.04~6.85, P=0.041). The overall incidence of TKI treatment-related adverse reactions was 40.58%(28/69), with a grade ≥3 adverse event rate of 11.59%(8/69). Common adverse reactions included rash, oral mucositis, and diarrhea.The incidence of TKI-related adverse reactions in the elderly group(17/39, 43.59%)was higher than that in the non-elderly group(11/30, 36.67%), but the difference was not statistically significant( χ2=1.038, P=0.196). Conclusions:Age is an independent predictor of PFS in patients with EGFR-mutant lung adenocarcinoma, and its effect is not interfered with by comorbidities or mutation subtypes.

Objective:To explore the value of three-dimensional automatic right ventricular quantitive analysis（3D Auto RVQ）technology in predicting the improvement of left ventricular ejection fraction（LVEF）in patients with heart failure with reduced ejection fraction（HFrEF）.Methods:A retrospective analysis was conducted on 89 HFrEF patients admitted to the Cardiology Department of Central China Fuwai Hospital of Zhengzhou University from April 2022 to June 2024. All patients received medication treatment and were further divided into heart failure with improved ejection fraction（HFimpEF）group and non HFimpEF group based on changes detected by echocardiography in LVEF after treatment. The clinical data，biological indicators，and medication treatment status of patients were collected，routine echocardiographic parameters and right ventricular strain parameters were measured，3D right ventricular ejection fraction（3D-RVEF），3D right ventricular stroke volume index（3D-RVSVI），3D right ventricular end-diastolic volume index（3D-RVEDVI），3D right ventricular end-systolic volume index（3D-RVESVI），3D tricuspid annular plane systolic excursion（3D-TAPSE），and 3D right ventricular fractional area change（3D-RVFAC）were measured using 3D Auto RVQ technology. The differences of the above parameters between the two groups were compared. The ROC curve was used to analyze the predictive efficiency of right ventricular parameters for HFimpEF，and the area under ROC curve（AUC）was calculated and compared. Logistic regression models were used to analyze the predictive value of right ventricular parameters for HFimpEF.Results:Compared with the non HFimpEF group，the HFimpEF group had a younger age，shorter heart failure course，a smaller proportion of males，New York Heart Association（NYHA）functional class ≥Ⅲ，and patients with concomitant coronary heart disease. The baseline LVEF，absolute value of two dimensional right ventricular global longitudinal strain（2D-RVGLS），3D-RVEF，3D-TAPSE，and 3D-RVSVI were higher in the HFimpEF group（all P<0.05）. ROC curve analysis showed that the AUC of 3D-RVEF for predicting HFimpEF was 0.858，and the predictive efficiency was higher than other right ventricular parameters. According to the Yoden index，the optimal cutoff value for predicting HFimpEF based on 3D-RVEF was 36.2%，with a corresponding sensitivity of 84.0% and specificity of 75.0%. After adjusting for clinical and other echocardiographic parameters，the logistic regression model showed that 3D-RVEF was an independent predictor of HFimpEF（ OR=1.435，95% CI=1.145-1.800， P<0.05）. Conclusions:The 3D-RVEF evaluated by 3D Auto RVQ technology has high predictive value for HFimpEF，which can provide a reference for clinical treatment，thereby improving the prognosis of HFrEF patients.

Objective: To explore the therapeutic mechanism of puerarin in treating rheumatoid arthritis (RA) rats based on the serine/tyrosine protein kinase B (AKT)-phosphorylated forkhead box protein O1 (FOXO1)-interleukin-9 (AKT-FOXO1-IL-9) signaling pathway. Methods : 36 rats were randomly divided into a blank group , a model group , a positive control group , and low , medium , and high dose groups of puerarin. Except for the blank group , the other groups were induced with type Ⅱ collagen to establish a RA rat model. After successful modeling , different doses of puerarin and methotrexate were given to treat the rats. The body mass and toe thickness of the rats were measured , and biochemical indicators of rat blood rheology were detected. X-ray was used to observe changes in rat joint morphology. Safranin green staining were used to observe the pathology of rat joint tissue. ELISA was used to detect the levels of IL-9 and rheumatoid factors in rat serum , and Western blot was used to detect changes in levels of AKT and FOXO1 . 36 rats were randomly divided into a blank group , a model group , a positive control group , and low , medium , and high dose groups of puerarin. Except for the blank group , the other groups were induced with type Ⅱ collagen to establish a RA rat model. After successful modeling , different doses of puerarin and methotrexate were given to treat the rats. The body mass and toe thickness of the rats were measured , and biochemical indicators of rat blood rheology were detected. X-ray was used to observe changes in rat joint morphology. Safranin green staining were used to observe the pathology of rat joint tissue. ELISA was used to detect the levels of IL-9 and rheumatoid factors in rat serum , and Western blot was used to detect changes in levels of AKT and FOXO1 . Results: Compared with the blank group , the model group had the lowest toe thickness , and X-ray images showed more obvious segmental stenosis and more severe marginal bone invasion ; scaly like changes appeared at the edges of joints stained with safranin green , accompanied by the exudation of inflammatory cells and increased proliferation and secretion of chondrocytes ; the expression levels of inflammatory factors IL-9 and rheumatoid factors were the highest , and the expression levels of AKT and FOXO1 proteins were the highest (P < 0. 05) . Compared with the model group , the toe thickness of rats treated with different doses of puerarin decreased ; X-ray images showed that the puerarin treatment group of rats showed improvement in plantar joint stenosis and marginal bone invasion ; the results of safranin green staining showed that after treatment with different doses of puerarin , the infiltration of inflammatory cells decreased , and the expression levels of inflammatory factor IL-9 , rheumatoid factors , AKT , and FOXO1 proteins decreased significantly ( P < 0. 05 ) , with the high-dose puerarin group showing the most significant difference. Compared with the high-dose puerarin group , the positive control group showed a significant decrease in the above results and statistical differences (P < 0. 05) . Conclusion Puerarin has a good therapeutic effect on rats with RA by inhibiting the AKT-FOXO1-IL-9 pathway. The high-dose puerarin group (60 mg/kg) has the best therapeutic effect and the results show a dose-response relationship.

Objective:To investigate the clinical characteristics and independent predictors of progression-free survival (PFS)in patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma in the real world.Methods:This was a retrospective observational study.The clinical data of 74 EGFR mutation-positive lung adenocarcinoma patients who visited the Geriatric Oncology Department of the Fisrt Affiliated Hospital of Nanjing Medical University from January 2020 to March 2025 were retrospectively collected.Retrospective analysis was performed on baseline clinical characteristics(gender, age, smoking history, stage, etc.), EGFR mutation types, and treatment follow-up data(PFS, treatment regimens). Descriptive statistics were used to summarize the baseline clinical characteristics of the patients.The distribution differences in clinical characteristics between the elderly group and the non-elderly group were compared.Kaplan-Meier survival curves were plotted with Log-rank test, and the Cox proportional hazards model was used to screen for independent prognostic factors.Results:The incidence of comorbidities in the elderly group(48.78%, 20/41)was significantly higher than that in the non-elderly group(24.24%, 8/33), with a statistically significant difference( χ2=4.681, P=0.031). No statistically significant differences were observed between groups in other variables[gender, stage, presence of multiple metastases, smoking history, Eastern cooperative oncology group (ECOG)score, treatment regimens, mutation types](all P>0.05). The median PFS (mPFS)in the elderly group was significantly shorter than that in the non-elderly group(18.20 months vs.26.78 months, Log-rank χ2=3.930, P=0.047). No significant differences in mPFS were found among gender, stage, presence of multiple metastases, smoking history, comorbidity status, ECOG score, treatment regimens, EGFR mutation types or types of tyrosine kinase inhibitor(TKI)(all P>0.05). Multivariate Cox regression further confirmed that advanced age(≥65 years)is an independent predictor of shortened PFS( HR=2.67, 95% CI: 1.04~6.85, P=0.041). The overall incidence of TKI treatment-related adverse reactions was 40.58%(28/69), with a grade ≥3 adverse event rate of 11.59%(8/69). Common adverse reactions included rash, oral mucositis, and diarrhea.The incidence of TKI-related adverse reactions in the elderly group(17/39, 43.59%)was higher than that in the non-elderly group(11/30, 36.67%), but the difference was not statistically significant( χ2=1.038, P=0.196). Conclusions:Age is an independent predictor of PFS in patients with EGFR-mutant lung adenocarcinoma, and its effect is not interfered with by comorbidities or mutation subtypes.

Objective:To explore the value of three-dimensional automatic right ventricular quantitive analysis（3D Auto RVQ）technology in predicting the improvement of left ventricular ejection fraction（LVEF）in patients with heart failure with reduced ejection fraction（HFrEF）.Methods:A retrospective analysis was conducted on 89 HFrEF patients admitted to the Cardiology Department of Central China Fuwai Hospital of Zhengzhou University from April 2022 to June 2024. All patients received medication treatment and were further divided into heart failure with improved ejection fraction（HFimpEF）group and non HFimpEF group based on changes detected by echocardiography in LVEF after treatment. The clinical data，biological indicators，and medication treatment status of patients were collected，routine echocardiographic parameters and right ventricular strain parameters were measured，3D right ventricular ejection fraction（3D-RVEF），3D right ventricular stroke volume index（3D-RVSVI），3D right ventricular end-diastolic volume index（3D-RVEDVI），3D right ventricular end-systolic volume index（3D-RVESVI），3D tricuspid annular plane systolic excursion（3D-TAPSE），and 3D right ventricular fractional area change（3D-RVFAC）were measured using 3D Auto RVQ technology. The differences of the above parameters between the two groups were compared. The ROC curve was used to analyze the predictive efficiency of right ventricular parameters for HFimpEF，and the area under ROC curve（AUC）was calculated and compared. Logistic regression models were used to analyze the predictive value of right ventricular parameters for HFimpEF.Results:Compared with the non HFimpEF group，the HFimpEF group had a younger age，shorter heart failure course，a smaller proportion of males，New York Heart Association（NYHA）functional class ≥Ⅲ，and patients with concomitant coronary heart disease. The baseline LVEF，absolute value of two dimensional right ventricular global longitudinal strain（2D-RVGLS），3D-RVEF，3D-TAPSE，and 3D-RVSVI were higher in the HFimpEF group（all P<0.05）. ROC curve analysis showed that the AUC of 3D-RVEF for predicting HFimpEF was 0.858，and the predictive efficiency was higher than other right ventricular parameters. According to the Yoden index，the optimal cutoff value for predicting HFimpEF based on 3D-RVEF was 36.2%，with a corresponding sensitivity of 84.0% and specificity of 75.0%. After adjusting for clinical and other echocardiographic parameters，the logistic regression model showed that 3D-RVEF was an independent predictor of HFimpEF（ OR=1.435，95% CI=1.145-1.800， P<0.05）. Conclusions:The 3D-RVEF evaluated by 3D Auto RVQ technology has high predictive value for HFimpEF，which can provide a reference for clinical treatment，thereby improving the prognosis of HFrEF patients.

Objective:To investigate the impact of sarcopenia on the short-term outcomes and long-term prognosis in cervical cancer patients undergoing concurrent chemoradiotherapy (CCRT).Methods:A total of 410 cervical cancer patients who received CCRT in Henan Provincial People′s Hospital between January 2017 and December 2021 were prospectively enrolled in this study. They were divided into the sarcopenia and non-sarcopenia groups based on the body muscle content measured using bioelectrical impedance analysis. Short-term outcomes were assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST), and acute adverse reactions were assessed based on the toxicity criteria of the Radiation Therapy Oncology Group (RTOG). CCRT termination or prolonged treatment associated with various acute adverse reactions were recorded. All patients were followed up with overall survival (OS) and progression-free survival (PFS) as endpoints. Finally, the survival rate was estimated and the association between sarcopenia and PFS was analyzed.Results:Among the patients, 152 (37.1%) had sarcopenia. Compared to the non-sarcopenia group, the sarcopenia group exhibited higher incidences of grade 2 or above acute adverse reactions in the lower gastrointestinal and hematological systems, CCRT termination, or prolonged treatment. In the non-sarcopenia group, 27 deaths were recorded, with an OS of 30 (18-36) months, a 3-year OS rate of 88.7%, and a 5-year OS rate of 85.6%. In the sarcopenia group, 23 deaths were found, with an OS of 24 (15-33) months, a 3-year OS rate of 83.8%, and a 5-year OS rate of 77.7%. There was no significant difference in survival curves between both groups ( P > 0.05). In the non-sarcopenia group, 52 cases of recurrence were recorded, with a PFS of 21 (12-33) months, a 3-year PFS rate of 77.9%, and a 5-year PFS rate of 71.0%. In the sarcopenia group, 41 cases of recurrence were found, with a PFS of 15 (10.5-24) months, a 3-year PFS rate of 69.0%, and a 5-year PFS rate of 56.5%. There was a significant difference in the PFS curves between both groups ( χ2 = 5.89, P = 0.015). Multivariate Cox regression analysis identified sarcopenia as an independent risk factor for PFS ( χ2 =4.33, P = 0.037). Conclusions:Sarcopenia increases the risks of acute adverse reactions and long-term recurrence in cervical cancer patients undergoing CCRT.

Cellular force transducer plays a crucial role in normal development of the follicles,which consists of integrin,focal adhesion,signal pathways and cytoskeleton.In follicle development,cellular force transducer converts force stimulation into biochemical signal,and activates the signal pathways to make cytoskeleton respond to stimulation.This process promotes various biological functions of germ cells,such as migration,meiosis and ovulation.This review summarizes the mechanism of follicles'development from two aspects,the role of cellular force transducer in the development of follicles and the related signal pathways,so as to provide a new idea for the further study of follicle development.

Objective:To sinicize the Modified Version of Motivation Scale for Stroke Rehabilitation (MORE) based on cognitive interviewing, and test its reliability and validity.Methods:The initial Chinese version of the MORE was developed based on the Brislin model and expert analysis method. From April to May 2021, purposive sampling was used to select 22 stroke patients from Linquan People's Hospital as the research subject for three rounds of semi-structured interviews. The Chinese version of the MORE was revised based on interview results to form the final version. From June 2021 to April 2023, convenience sampling was used to select 200 stroke patients from Linquan People's Hospital for investigation, to test the reliability and validity of the scale.Results:After three rounds of semi-structured interviews, a Chinese version of the MORE consisting of 17 items was formed. The content validity index at the item level was 0.913 to 1.000, and the content validity index at the scale level was 0.921. Three common factors were extracted using the maximum variance orthogonal rotation, with a cumulative variance contribution rate of 77.318%. The Cronbach's α coefficient of the Chinese version of the MORE was 0.937, the half coefficient was 0.898, and the test-retest reliability was 0.911.Conclusions:The understanding of the Chinese version of the MORE by stroke patients is comprehensively understood through cognitive interviewing. The reliability and validity test finds that the Chinese version of the MORE is an effective and reliable scale for evaluating the rehabilitation motivation of stroke patients, providing a reference basis for analyzing the influencing factors of rehabilitation motivation of stroke patients and formulating prevention and intervention measures.

Objective:To evaluate the right ventricular function in patients with dilated cardiomyopathy (DCM) by four-dimensional automatic right ventricular quantitative analysis (4D Auto RVQ), and compare with the right ventricular ejection fraction measured by cardiac magnetic resonance (CMR-RVEF), and to explore the clinical application value of 4D Auto RVQ technique in evaluating the right ventricular function of patients with DCM.Methods:A prospective study was conducted to select 52 patients with DCM who were treated in Fuwai Central China Cardiovascular Hospital of Zhengzhou University from March to October 2022 as DCM group, and 52 healthy volunteers were selected as the control group during the same period. The four-dimensional right ventricular ejection fraction (4D-RVEF), right ventricular stroke volume index (RVSVI), right ventricular end-diastolic volume index (RVEDVI), right ventricular end-systolic volume index (RVESVI), four-dimensional right ventricular basal diameter (4D-RVDd-base), four-dimensional right ventricular middle diameter (4D-RVDd-mid), four-dimensional right ventricular long axis diameter (4D-RVLd), four-dimensional tricuspid annular plane systolic excursion (4D-TAPSE) and four-dimensional right ventricular fractional area change (4D-RVFAC) were obtained by 4D Auto RVQ technique. The differences of the above parameters between DCM group and control group were compared.Pearson linear correlation analysis was used to evaluate the correlation between echocardiographic parameters and CMR-RVEF. The ROC curve was used to find the most sensitive parameters for evaluating right ventricular function, and the area under the ROC curve ( AUC ) was calculated and compared.Results:Compared with the control group, RVEDVI, RVESVI, 4D-RVDd-base and 4D-RVDd-mid in the DCM group were increased, and the absolute values of 4D-RVEF, 4D-TAPSE, 4D-RVFAC, right ventricular global longitudinal strain(RVGLS) and right ventricular free wall longitudinal strain(RVFWLS) were decreased (all P<0.05). Correlation analysis showed that 4D-RVEF was positively correlated with CMR-RVEF ( r=0.711, P<0.05). ROC curve analysis showed that 4D-RVEF was superior to other parameters in evaluating right ventricular function in DCM patients (AUC: 0.916). Conclusions:4D Auto RVQ technique can quantitatively evaluate right ventricular function in DCM patients. 4D-RVEF has a significant correlation with CMR-RVEF, and 4D-RVEF has the best efficacy in evaluating right ventricular function in DCM patients.

Objective:To explore the necessity and feasibility of clinical nutrition pharmacist-involved consultation, and evaluate the impact on clinical outcome.Methods:Patients who received the nutritional consultation involving pharmacists at Shanxi Bethune Hospital between 2019 and 2021 were retrospectively enrolled. Patient clinical characteristics, distribution, consultation purpose and nutrition management regimen, and clinical outcomes were collected and analyzed.Results:There was increasing utilization of nutrition pharmacist-involved consultations and referrals to pharmacy clinic over the three years. An average of 95.3% of consultation advices were accepted. Over 90% of patients who were scored 3-6 points with Nutritional Risk Screening 2002 benefited from such consultations. Patients with tumors, elderly patients, and patients with digestive system disorders showed the most benefit from nutritional consultations. The purpose of consultation was focused on the development of individualized nutritional management plans, which brought about improvement in patient's nutritional indicators.Conclusion:There is a strong demand for nutritional pharmacy consultation in large-scale comprehensive hospitals, and the standardized consultation workflow paves the way for comprehensive and individualized nutrition therapy.